Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

792 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.
Tardif JC, Rhéaume E, Lemieux Perreault LP, Grégoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L'Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dubé MP. Tardif JC, et al. Circ Cardiovasc Genet. 2015 Apr;8(2):372-82. doi: 10.1161/CIRCGENETICS.114.000663. Epub 2015 Jan 11. Circ Cardiovasc Genet. 2015. PMID: 25583994 Clinical Trial.
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Tardif JC, Grégoire J, Schwartz L, Title L, Laramée L, Reeves F, Lespérance J, Bourassa MG, L'Allier PL, Glass M, Lambert J, Guertin MC; Canadian Antioxidant Restenosis Trial (CART-1) Investigators. Tardif JC, et al. Circulation. 2003 Feb 4;107(4):552-8. doi: 10.1161/01.cir.0000047525.58618.3c. Circulation. 2003. PMID: 12566365 Clinical Trial.
Vascular protectants for the treatment of atherosclerosis.
Tardif JC, Grégoire J, Lavoie MA, L'Allier PL. Tardif JC, et al. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):385-92. doi: 10.1586/14779072.1.3.385. Expert Rev Cardiovasc Ther. 2003. PMID: 15030266 Review.
792 results